Britain and America have secured a significant trade agreement that will maintain zero import taxes on British pharmaceutical products being sold in the US market.
Key Provisions of the Deal
As part of the deal, the UK has agreed to boost spending on medicines through the public health system. This move ensures that import taxes on these key exports will remain at nothing for a period of 36 months.
This deal is in response to previous warnings to hike tariffs on patented pharmaceutical imports, with increases floated as high as one hundred percent.
"This arrangement with the Britain bolsters the worldwide climate for new treatments and introduces much-needed equity to U.S.–U.K. pharmaceutical trade," an announcement noted.
Economic Impact
Drugs are one of the UK's biggest exports to the US, which is by far the primary market for leading British pharmaceutical firms.
Export figures show that in the 12 months leading up to September, the UK exported medicines totaling £11.1bn to the US. This amount made up 17.4% of British export trade in that span.
"This guarantee secures work, boosts investment and paves the way for the UK to become a global hub for medical research," a government official stated.
Specific UK Commitments
The deal includes several notable changes from the United Kingdom:
- Price Threshold Increase: The UK will raise the cost ceiling at which it considers new therapies to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a target to double overall health service expenditure on medicines from 0.3 percent of GDP to 0.6 percent over the next decade.
- Rebate Cap: The sum manufacturers must refund to the NHS to control costs will be limited at 15%. Last year, repayments were more than twenty percent.
Recent Tensions
The deal takes place against a long-running dispute between the sector and the ministers over spending levels and regulatory access.
These tensions were exacerbated by arguments that US customers were paying a premium for the equivalent treatments than consumers in the Britain and the EU.
Recently, several major manufacturing plans in the UK have been delayed or cancelled, while multi-billion-dollar expansions have been directed toward American operations.
A senior figure acknowledged that the NHS needed to spend more on treatments, noting that its spending on drugs had shrunk as a share of its overall budget over the last ten years.
